Continuous and semi-continuous cell culture for production of blood clotting factors

Journal of Biotechnology

Volumn 213, Issue , 2015, Pages 20-27

  Desai, Sunil G ^a  

^a PFIZER INC   (United States)

Author keywords

BeneFIX; Blood clotting factors; Continuous bioprocessing; Factor IX, factor VIII; Gamma carboxylation; Perfusion; Post translational modifications; Re feed; ReFacto; ReFacto AF; Semi continuous bioprocessing; Xyntha

Indexed keywords

BLOOD; CARBOXYLATION; CELL CULTURE;

BENEFIX; BLOOD CLOTTING; CONTINUOUS BIOPROCESSING; FACTOR VIII; PERFUSION; POST-TRANSLATIONAL MODIFICATIONS; REFACTO; REFACTO AF; SEMI-CONTINUOUS; XYNTHA;

CONTINUOUS CELL CULTURE;

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT FACTOR VIII SQ;

ANIMAL CELL; ARTICLE; BATCH CELL CULTURE; BIOREACTOR; BIOTECHNOLOGICAL PRODUCTION; CELL CULTURE EQUIPMENT; CELL GROWTH; CELL LINE; CHO CELL LINE; CHROMATOGRAPHY; CONTAMINATION; CONTINUOUS CELL CULTURE; CONTINUOUS CULTURE; CONTINUOUS PROCESS; CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG STRUCTURE; FEMALE; GENETIC STABILITY; GROWTH RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PRODUCTIVITY; REACTOR OPERATION; SEMI CONTINUOUS CELL CULTURE; ANIMAL; BIOSYNTHESIS; CELL CULTURE TECHNIQUE; CRICETULUS;

ANIMALS; BIOREACTORS; CELL CULTURE TECHNIQUES; CHO CELLS; CRICETULUS; FACTOR IX; FACTOR VIII;

EID: 84935715239     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2015.02.021     Document Type: Article

References (9)

1. Bond M., Jankowski M., Patel H., Karnik S., Strang A., Xu B., Rouse J., Koza S., Letwin B., Steckert J., Amphlett G., Scoble H. Biochemical characterization of recombinant factor IX. Semin. Hematol. 1998, 35(2 (Suppl. 2)):11-17.
2. Brandsetter H., Bauer M., Huber R., Lollar P., Bode W. X-ray structure of clotting factor IXa: active site and module structure to Xase activity and hemophilia B. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:9796-9800.
3. Eriksson R.K., Fenge C., Lindner-Olsson E., Ljungqvist C., Rosenquist J., Smeds A.L., Östlin A., Charlebois T., Leonard M., Kelley B.D., Ljungqvist A. The manufacturing process for B-domain deleted recombinant factor VIII. Semin. Hematol. 2001, 38(2 (Suppl. 4)):24-31.
4. Harrison S., Adamson S., Bonam D., Brodeur S., Charlebois T., Clancy B., Costigan R., Drapeau D., Hamilton M., Hanley K., Kelley B., Knight A., Leonard M., McCarthy M., Oakes P., Sterl K., Switzer M., Walsh R., Foster W. The manufacturing process for recombinant factor IX. Semin. Hematol. 1998, 35(2 (Suppl. 2)):4-10.
5. Kelley B., Jankowski M., Booth J. An improved manufacturing process for Xyntha/ReFacto AF. Hemophilia 2009, 1-9.
6. Animal Cell Technology: From Biopharmaceuticals to Gene Therapy 2008, 252. C. Leda, M. Angela, A. Elisabeth, B. Mike (Eds.).
7. Orlova N.A., Kovnir S.V., Vorobiev I.I., Gabibov A.G. Coagulation factor IX for hemophilia B therapy. Acta Naturae 2012, 4-2(13):62-73.
8. Orlova N.A., Kovnir S.V., Vorobiev I.I., Gabibov A.G., Vorobiev A.I. Blood clotting factor VIII: from evolution to therapy. Acta Naturae 2013, 5-2(17):19-39.
9. Recht M., Nemes L., Matysiak M., Manco-Johnson M., Lusher J., Smith M., Mannucci P., Hay C., Abshire T., O'Brien A., Hayward B., Udata C., Roth D.A., Arkin S. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009, 15:869-880.